DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation.

Autor: Rojas C; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA.; Department of Molecular and Comparative Pathobiology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Barnaeva E; National Center for Advancing Translational Sciences (NCATS), National Institute of Health, Bethesda, MD, 20892-3370, USA., Thomas AG; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Hu X; National Center for Advancing Translational Sciences (NCATS), National Institute of Health, Bethesda, MD, 20892-3370, USA., Southall N; National Center for Advancing Translational Sciences (NCATS), National Institute of Health, Bethesda, MD, 20892-3370, USA., Marugan J; National Center for Advancing Translational Sciences (NCATS), National Institute of Health, Bethesda, MD, 20892-3370, USA., Chaudhuri AD; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Yoo SW; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Hin N; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Stepanek O; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Wu Y; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Zimmermann SC; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA.; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Gadiano AG; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Tsukamoto T; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA.; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Rais R; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA.; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA., Haughey N; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. nhaughe1@jhmi.edu., Ferrer M; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. marc.ferrer@nih.gov., Slusher BS; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. bslusher@jhmi.edu.; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. bslusher@jhmi.edu.; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. bslusher@jhmi.edu.; Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. bslusher@jhmi.edu.; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. bslusher@jhmi.edu.; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA. bslusher@jhmi.edu.

Publikováno v: Scientific reports [Sci Rep] 2018 Dec 07; Vol. 8 (1), pp. 17715. Date of Electronic Publication: 2018 Dec 07.